What is the recommended administration of estrogen therapy for recurrent urinary tract infections (rUTI) in postmenopausal women and what other evidence-based preventive measures are available for this group?

Vaginal Estrogen Administration for rUTI Prevention in Postmenopausal Women

Use vaginal estrogen replacement in postmenopausal women to prevent recurrent UTI, administered topically at weekly doses of ≥850 µg for optimal efficacy. 1, 2

Route of Administration

Vaginal estrogen is strongly recommended; oral estrogen is NOT effective for rUTI prevention. 1, 3

• Vaginal administration reduces UTI recurrence significantly (RR 0.25-0.64 compared to placebo), while oral estrogen shows no benefit (RR 1.08) 3
• The vaginal route works by restoring lactobacilli, lowering vaginal pH from 5.5 to 3.8, and reducing gram-negative bacterial colonization from 67% to 31% 4
• Importantly, vaginal estrogen does not increase serum estrogen levels, avoiding systemic risks including breast cancer recurrence or endometrial hyperplasia 1

Specific Formulations and Dosing

Available vaginal estrogen options include: 5, 2

• Vaginal cream (estriol or conjugated estrogens)
• Vaginal ring (estradiol-releasing)
• Vaginal pessaries/tablets

Optimal dosing: Weekly doses of ≥850 µg are associated with best outcomes, with 51-100% of patients remaining UTI-free during treatment 2

Typical regimen: Intravaginal estriol cream administered regularly showed 0.5 UTI episodes per patient-year versus 5.9 in placebo group (P < 0.001) 4

Common Side Effects and Adherence

Expected adverse effects include: 4, 3

• Breast tenderness
• Vaginal bleeding or spotting
• Vaginal irritation, burning, or itching
• Nonphysiologic discharge

Important caveat: Dropout rates of 17-28% occur due to side effects, requiring patient counseling about tolerability 4

---

Evidence-Based Non-Antimicrobial Preventive Measures

Hierarchical Approach to Prevention

The EAU 2024 guidelines recommend attempting interventions in this specific order: 1

1. Counseling on risk factor avoidance and behavioral modifications
2. Non-antimicrobial measures
3. Antimicrobial prophylaxis (only when non-antimicrobial interventions fail)

Strong Evidence-Based Interventions

Methenamine Hippurate (Strong Recommendation)

Use methenamine hippurate to reduce rUTI episodes in women without urinary tract abnormalities 1

• Dosing: 1 gram twice daily 1
• Can be combined with vaginal estrogen for additive effect 1

Immunoactive Prophylaxis (Strong Recommendation)

Use immunoactive prophylaxis (OM-89/Uro-Vaxom) to reduce rUTI in all age groups 1

• Oral immunostimulant OM-89 decreases rUTI (RR 0.61,95% CI 0.48-0.78) with good safety profile 1
• Appears to be the most promising non-antimicrobial option based on meta-analysis 1

Weak Evidence-Based Interventions

Probiotics (Weak Recommendation)

Advise patients on lactobacillus-containing probiotics with proven efficacy for vaginal flora regeneration 1

• Specific strains: Lactobacillus rhamnosus GR-1 or Lactobacillus reuteri RC-14 1
• Can be used once or twice weekly for prophylaxis 1
• May be combined with vaginal estrogen in postmenopausal women 1

Cranberry Products (Weak Recommendation)

Cranberry products may reduce rUTI episodes, but evidence is low quality with contradictory findings 1

• Minimum dose: 36 mg/day proanthocyanidin A 1
• Patients must be informed about inconsistent evidence 1

D-Mannose (Weak Recommendation)

D-mannose may reduce rUTI episodes, but evidence is weak and contradictory 1

• Works by inhibiting bacterial adhesion to uroepithelial cells 1
• Patients should be counseled about limited evidence 1

Advanced Interventions for Refractory Cases

Intravesical Instillations (Weak Recommendation)

Use endovesical instillations of hyaluronic acid or hyaluronic acid/chondroitin sulfate combination when less invasive approaches fail 1

• Reduces UTI rate per patient-year (MD 3.41,95% CI 4.33 to 2.49) 1
• Increases time to recurrence (MD 187.35 days, 95% CI 94.33 to 280.37) 1
• Patients must be informed that further confirmatory studies are needed 1

Antimicrobial Prophylaxis (When Non-Antimicrobial Measures Fail)

Use continuous or postcoital antimicrobial prophylaxis only after non-antimicrobial interventions have failed 1

Preferred agents (in order): 1

• Nitrofurantoin 50 mg daily
• Trimethoprim-sulfamethoxazole 40/200 mg daily
• Trimethoprim 100 mg daily

Avoid fluoroquinolones and cephalosporins as first-line prophylaxis due to antimicrobial stewardship concerns 1

Consider rotating antibiotics at 3-month intervals to prevent antimicrobial resistance 1

Behavioral Modifications

Counsel patients on: 1

• Adequate hydration (especially in premenopausal women) 1
• Voiding after intercourse
• Avoiding prolonged urine retention
• Controlling blood glucose in diabetics
• Avoiding spermicides (consider alternative contraception) 1
• Avoiding harsh vaginal cleansers that disrupt normal flora 1

Critical Pitfalls to Avoid

Do NOT perform extensive routine workup (cystoscopy, full abdominal ultrasound) in women younger than 40 years with rUTI and no risk factors 1

Do NOT treat asymptomatic bacteriuria in women with rUTI, as this fosters antimicrobial resistance and increases rUTI episodes 1

Do NOT use oral estrogen for rUTI prevention—it is ineffective and only vaginal administration works 1, 3